Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.59 |
| ▸ | DRD1 | P21728 | 1/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | CASR | P41180 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1357332 | 1.00 | CYP3A4 (0.59) | CYP3A4LMNACHRM2HTR1AADRA2A | |
| SCHEMBL1784975 | 1.00 | CYP3A4 (0.59) | CYP3A4LMNACHRM2HTR1AADRA2A | |
| SCHEMBL16604868 | 0.82 | CYP3A4 (0.40) | CYP3A4LMNACHRM2HTR1AADRA2A | |
| SCHEMBL5471668 | 0.82 | CYP3A4 (0.76) | CYP3A4LMNACHRM2HTR1AADRA2A | |
| SCHEMBL3881700 | 0.82 | CYP3A4 (0.76) | CYP3A4LMNACHRM2HTR1AADRA2A | |
| SCHEMBL24406703 | 0.82 | CYP3A4 (0.76) | CYP3A4LMNACHRM2HTR1AADRA2A | |
| SCHEMBL3881699 | 0.82 | CYP3A4 (0.76) | CYP3A4LMNACHRM2HTR1AADRA2A | |
| SCHEMBL13342870 | 0.81 | CYP3A4 (0.59) | CYP3A4LMNACHRM2HTR1AADRA2A | |
| SCHEMBL8119644 | 0.81 | CYP3A4 (0.53) | CYP3A4LMNACHRM2HTR1AADRA2A | |
| SCHEMBL479277 | 0.81 | CYP3A4 (0.53) | CYP3A4LMNACHRM2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114828959-B | 3- (5-methoxy-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivative and application thereof | 诺华股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| EP-4076650-B1 | 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| US-11566022-B2 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2023-01-31 | — | — | US | disclosed |
| US-20220402904-A1 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | NOVARTIS AG (CH) | 2022-12-22 | — | — | US | disclosed |
| US-20220305018-A1 | PYRAZOLE PYRIMIDINE COMPOUNDS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2022-09-29 | — | — | US | disclosed |
| WO-2022197641-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-AMINE DERIVATIVES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS AND/OR INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES | RAPT THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| CN-114828959-A | 3- (5-methoxy-1-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| WO-2021124172-A1 | 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2021-06-24 | — | — | WO | disclosed |
| US-8012980-B2 | Isoquinolinone derivatives | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| EP-2253614-A1 | Inhibitors of IAP | Novartis AG (CH) | 2010-11-24 | — | — | EP | disclosed |
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| WO-2009140447-A1 | IMMUNOMODULATION BY IAP INHIBITORS | NOVARTIS AG (CH) | 2009-11-19 | — | — | WO | disclosed |
| EP-2065368-A1 | Inhibitors of IAP | Novartis Ag (CH) | 2009-06-03 | — | — | EP | disclosed |
| US-7144899-B2 | Thrombin inhibitors | MERCK & CO., INC. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20040073025-A1 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | DCK, MCL1, DTYMK | CYP3A4 3171/4885LMNA 4241/4885CHRM2 4852/4885 |
| US-11566022-B2 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | HBZ, ZFX, HBG1 | CYP3A4 3888/4885LMNA 1203/4885CHRM2 4757/4885 |
| US-20220305018-A1 | PYRAZOLE PYRIMIDINE COMPOUNDS AND USES THEREOF | DCK, MCL1, DTYMK | CYP3A4 3171/4885LMNA 4241/4885CHRM2 4852/4885 |
| US-20220402904-A1 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | HBZ, ZFX, HBG1 | CYP3A4 3862/4885LMNA 1213/4885CHRM2 4703/4885 |
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | SDHA, NQO1, CYP3A5 | CYP3A4 30/4885LMNA 1339/4885CHRM2 3047/4885 |
| US-20040073025-A1 | Thrombin inhibitors | F2, F11, F10 | CYP3A4 2153/4885LMNA 1769/4885CHRM2 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.